Allianz Asset Management
CTKB icon

Allianz Asset Management’s Cytek Biosciences CTKB Stock Holding History

Allianz Asset Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-74,000
Closed -$297K – 2063
2025
Q1 		$297K Buy
74,000
+23,300
+46% +$121K ﹤0.01% 2045
2024
Q4 		$329K Buy
50,700
+13,300
+36% +$79.2K ﹤0.01% 1978
2024
Q3 		$207K Hold
37,400
– – ﹤0.01% 2080
2024
Q2 		$209K Buy
+37,400
New +$225K ﹤0.01% 2026
2022
Q3 		– Sell
-30,415
Closed -$326K – 1933
2022
Q2 		$326K Buy
+30,415
New +$303K ﹤0.01% 1994

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Allianz Asset Management's CTKB Position: Q2 2025 in Review

Allianz Asset Management sold out of Cytek Biosciences (CTKB) in Q2 2025, closing a stake of 74,000 shares — an estimated $297K sold.

Allianz Asset Management first reported a position in CTKB in Q2 2022 and held it in 5 quarters. The position peaked at $329K in Q4 2024. 158 funds tracked by Wall St. Rank hold CTKB as of Q2 2025.

  • Allianz Asset Management reported no remaining Cytek Biosciences position as of Q2 2025 after selling out during the quarter.
  • Allianz Asset Management sold 74,000 Cytek Biosciences shares in Q2 2025, an estimated $297K.
  • Allianz Asset Management first reported a position in Cytek Biosciences in Q2 2022 and held it in 5 quarters.
  • Allianz Asset Management's Cytek Biosciences position peaked at $329K in Q4 2024.
  • 158 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2025.

Based on Allianz Asset Management's 13F filing for Q2 2025, filed 28 Jul 2025.